(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 March 2018 (29.03.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/057669 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *A61P 35/00* (2006.01)
A61P 29/00 (2006.01) *A61P 37/06* (2006.01)

(21) International Application Number:
PCT/US2017/052592

(22) International Filing Date:
20 September 2017 (20.09.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/397,752 21 September 2016 (21.09.2016) US
62/515,480 05 June 2017 (05.06.2017) US

(71) Applicant: **ALEXO THERAPEUTICS INC.** [US/US]; 951 Gateway Boulevard, Suite 201, South San Francisco, CA 94080 (US).

(72) Inventors: **PONS, Jaume**; c/o Alexo Therapeutics Inc., 951 Gateway Boulevard, Suite 201, South San Francisco, CA 94080 (US). **SIM, Bang Janet**; c/o Alexo Therapeutics Inc., 951 Gateway Boulevard, Suite 201, South San Francisco, CA 94080 (US). **WAN, Hong**; c/o Alexo Therapeutics Inc., 951 Gateway Boulevard, Suite 201, South San Francisco, CA 94080 (US). **KUO, Tracy Chia-Chien**; c/o Alexo Therapeutics Inc., 951 Gateway Boulevard, Suite 201, South San Francisco, CA 94080 (US). **KAUDER, Steven Elliot**; c/o Alexo Therapeutics Inc., 951 Gateway Boulevard, Suite 201, South San Francisco, CA 94080 (US). **HARRIMAN, William Don**; c/o Crystal Bioscience Inc., 5980 Horton Street, Suite 405, Emeryville, CA 94608-2059 (US). **IZQUIERDO, Shelley**; c/o Crystal Bioscience Inc., 5980 Horton Street, Suite 405, Emeryville, CA 94608-2059 (US).

(74) Agent: **JONES, Kevin** et al.; Morrison& Foerster LLP, 425 Market Street, San Francisco, CA 94105-2482 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: ANTIBODIES AGAINST SIGNAL-REGULATORY PROTEIN ALPHA AND METHODS OF USE




FIG. 16

(57) Abstract: Provided herein, *inter alia*, are isolated antibodies that bind an extracellular domain of a human SIRP-α v1 polypeptide (e.g., the D1 domain), an extracellular domain of a human SIRP-α v2 polypeptide, or both. In some embodiments, the antibodies also bind an extracellular domain of a monkey SIRP-α polypeptide, an extracellular domain of a mouse SIRP-α polypeptide, an extracellular domain of a human SiRP-β polypeptide, and/or an extracellular domain of a human SIRP-γ polypeptide. In some embodiments, the antibodies block or do not binding between an extracellular domain of a human SIRP-α polypeptide and an IgSF domain of a human CD47 polypeptide, while in some embodiments, the antibodies reduce the affinity of a human SIRP-α polypeptide for binding an IgSF domain of a human CD47 polypeptide. Further provided herein are methods, polynucleotides, vectors, and host cells related thereto.

WO 2018/057669 A1

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*